Biogen Parkinson’s Trial Failure and Genentech Research Grants

Biogen and Denali Therapeutics announced on May 21, 2026, that an experimental therapy designed to treat Parkinson’s disease failed to slow the progression of the degenerative brain disorder in a randomized trial. The results represent a significant setback for a scientific strategy that had generated substantial interest among academic researchers and patient advocates.

The study involved 648 adults living with Parkinson’s disease. Participants were randomized to receive either a placebo or a medication specifically targeting a protein known as LRRK2.

The focus on the LRRK2 protein stems from research conducted in 2004, when scientists discovered that mutations in the LRRK2 gene can lead to a rare, inherited version of Parkinson’s disease. This discovery laid the groundwork for a broader hypothesis tested in 2018, when another group of researchers suggested that blocking this protein could potentially provide benefits to all patients with the disease, regardless of whether they have the specific genetic mutation.

The failure of the recent randomized trial to slow the disorder challenges the theory that targeting LRRK2 is a viable path for treating the general Parkinson’s patient population.

In a separate development within the pharmaceutical sector, Genentech has launched an initiative to fund academic research that aligns with specific corporate and policy perspectives. In May 2026, the company began offering grants of up to $125,000 to academics and researchers to produce papers on several predefined topics.

According to a request for proposals, Genentech is seeking rigorous, independent work that focuses on three primary areas:

• The potential consequences of U.S. Pricing policies on future medical innovation.
• The concept of pharmaceutical discovery as a strategic national asset.
• The inherent risks associated with research and development (R&amp. D).

The solicitation, which carries a submission deadline of June 30, 2026, is noted for its directness. While pharmaceutical companies often engage with academia, this particular effort explicitly seeks research designed to address specific talking points that may be used to influence policymakers on Capitol Hill, rather than soliciting open research topics that might eventually align with corporate goals.